Historique
Rapport
WHO expert committee on drug dependence. 44th report
Auteur(s) :
OMS / WHO (Organisation mondiale de la santé / World Health Organization) ;
Forty-fourth meeting of the WHO Expert Committee on Drug Dependence (ECDD) (convened virtually on 11-15 October 2021; coordinated from WHO headquarters, Geneva, Switzerland)
Année
2022
Page(s) :
204 p.
Langue(s) :
Anglais
Éditeur(s) :
Genève : OMS / WHO
Collection :
Rapports techniques / Technical report series, 1038
ISBN :
978-92-4-004283-4
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
INTERNATIONAL
Thésaurus mots-clés
RECOMMANDATION
;
CONTROLE DES STUPEFIANTS
;
DROIT INTERNATIONAL
;
CANNABIS
;
DROGUES DE SYNTHESE
;
KRATOM
;
CHIMIE
;
POTENTIEL ADDICTIF
;
FABRICATION
;
PHARMACOLOGIE
;
ETUDE DE CAS
;
TOXICOLOGIE
Résumé :
The International Drug Control Conventions of 1961 and 1971 mandate WHO to make recommendations to the United Nations Secretary-General on the need for and level of international control of psychoactive substances according to the advice of its independent scientific advisory body, the ECDD.
At its forty-fourth meeting, the ECDD critically reviewed five new psychoactive substances, comprising one synthetic cannabinoid receptor agonist (4F-MDMB-BICA), two novel synthetic opioids (brorphine and metonitazene) and two cathinones/stimulants (eutylone and benzylone). These substances had not previously been reviewed formally by WHO and are currently not under international control. A critical review of the use of each substance and its effects was undertaken so that the Expert Committee could determine whether the information available on these substances justified scheduling or a change in scheduling from that in the 1961 or 1971 Convention. In addition, the meeting pre-reviewed kratom, mitragynine and 7-hydroxymitragynine and phenibut to determine whether the current information justified a critical review.
After the Forty-fourth Meeting of the ECDD, WHO endorsed and submitted the following recommendations to the United Nations Secretary General for further consideration by the Commission on Narcotic Drugs.
At its forty-fourth meeting, the ECDD critically reviewed five new psychoactive substances, comprising one synthetic cannabinoid receptor agonist (4F-MDMB-BICA), two novel synthetic opioids (brorphine and metonitazene) and two cathinones/stimulants (eutylone and benzylone). These substances had not previously been reviewed formally by WHO and are currently not under international control. A critical review of the use of each substance and its effects was undertaken so that the Expert Committee could determine whether the information available on these substances justified scheduling or a change in scheduling from that in the 1961 or 1971 Convention. In addition, the meeting pre-reviewed kratom, mitragynine and 7-hydroxymitragynine and phenibut to determine whether the current information justified a critical review.
After the Forty-fourth Meeting of the ECDD, WHO endorsed and submitted the following recommendations to the United Nations Secretary General for further consideration by the Commission on Narcotic Drugs.